Investors eyeing a purchase of Applied Optoelectronics Inc (AAOI - Get Report) stock, but cautious about paying the going market price of $44.05/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the September put at the $35 strike, which has a bid at the time of this writing of $2.65. Collecting that bid as the premium represents a 7.6% return against the $35 commitment, or a 18.7% annualized rate of return (at Stock Options Channel we call this the YieldBoost).Selling a put does not give an investor access to AAOI's upside potential the way owning shares would, because the put seller only ends up owning shares in the scenario where the contract is exercised. And the person on the other side of the contract would only benefit from exercising at the $35 strike if doing so produced a better outcome than selling at the going market price. ( Do options carry counterparty risk? This and six other common options myths debunked). So unless Applied Optoelectronics Inc sees its shares fall 20.3% and the contract is exercised (resulting in a cost basis of $32.35 per share before broker commissions, subtracting the $2.65 from $35), the only upside to the put seller is from collecting that premium for the 18.7% annualized rate of return. Below is a chart showing the trailing twelve month trading history for Applied Optoelectronics Inc, and highlighting in green where the $35 strike is located relative to that history: The chart above, and the stock's historical volatility, can be a helpful guide in combination with fundamental analysis to judge whether selling the September put at the $35 strike for the 18.7% annualized rate of return represents good reward for the risks. We calculate the trailing twelve month volatility for Applied Optoelectronics Inc (considering the last 252 trading day closing values as well as today's price of $44.05) to be 70%. For other put options contract ideas at the various different available expirations, visit the AAOI Stock Options page of StockOptionsChannel.com. In mid-afternoon trading on Thursday, the put volume among S&P 500 components was 819,814 contracts, with call volume at 819,814, for a put:call ratio of 0.72 so far for the day, which is above normal compared to the long-term median put:call ratio of .65. In other words, if we look at the number of call buyers and then use the long-term median to project the number of put buyers we'd expect to see, we're actually seeing more put buyers than expected out there in options trading so far today. Find out which 15 call and put options traders are talking about today.
TheStreet’s Fundamentals of Investing Course will teach you the keys to making the right decisions in any market.
TheStreet’s Personal Finance Essentials Course will teach you money management basics and investing strategies to help you avoid major financial pitfalls.
TheStreet Courses offers dedicated classes designed to improve your investing skills, stock market knowledge and money management capabilities.
More from Stocks
Tesla Shares Extend Skid as Morgan Stanley Lays Out $16.4 Billion 'Bear Case'
Tesla shares are hit with yet another bearish broadside Tuesday, as analysts at Morgan Stanley weigh in on the clean-energy carmaker's prospects in China and the health of its debt-laden balance sheet.
Watching Huawei's Stay of Execution and Telco Consolidation: Market Recon
Is the temporary license granted for U.S. exports to Huawei part of the ongoing attempt to reach a trade deal -- or is it early stages of what might end up as a protracted cold war?
Which Technology Stocks Make Better Investments During a Trade War?
Here's your playbook for gearing a long-term portfolio during a trade war.
Alphabet Stock Is Just Too Cheap After Its Recent Selloff
The tech giant remains an absolute cash cow with over $113 billion on the balance sheet and trades for a reasonable 25x forward earnings. The post-earnings selloff is overdone.
Merck to Acquire Peloton Therapeutics for About $1B in Cash
Merck agrees to buy privately held Peloton Therapeutics for $1 billion in cash, giving it access to Peloton's molecular therapy treatments for patients with cancer and other non-oncology diseases.